Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Kandolf, L; Ascierto, PA; Bastholt, L; Gavrilova, I; Haanen, J; Hauschild, A; Herceg, D; Hoeller, C; Suljevic, AJ; Kessels, J; Krajsova, I; Kukushkina, M; Lallas, A; Lorigan, P; Mangana, J; Marquez-Rodas, I; Mazilu, L; Mohr, P; Bylaite-Bucinskiene, M; Ocvirk, J; Olah, J; Putnik, K; Rutkowski, P; Saiag, P; Samolyenko, I; Schwarze, JK; Stojkovski, I; Saric, NC; Vieira, R; Weichenthal, M; Garbe, C.

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology

EUROPEAN JOURNAL OF CANCER. 2025; 216: Nº de citas: 4 [doi:10.1016/j.ejca.2024.115124]

Hortobagyi, GN; Lacko, A; Sohn, J; Cruz, F; Borrego, MR; Manikhas, A; Park, YH; Stroyakovskiy, D; Hurvitz, S; Barrios, C; Untch, M; Moroose, R; Yardley, DA; Visco, F; Chia, S; Huang, CS; Fasching, PA; Parnizari, F; Crown, J; Zarate, JP; Bardia, A; Loi, S; Li, Z; Martin, M; Xu, B; Im, SA; Waters, S; Chakravartty, A; Slamon, D.

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

ANNALS OF ONCOLOGY. 2025; 36(2): 149-157 Nº de citas: 75 [doi:10.1016/j.annonc.2024.10.015]

Lynce, F; Martinez-Sáez, O; Walbaum, B; Brasó-Maristany, F; Waks, AG; Villagrasa, P; Javierre, GV; Sanfeliu, E; Galvan, P; Paré, L; Anderson, LM; Perou, CM; Parker, JS; Vivancos, A; Dilullo, MK; Pernas, S; Winer, EP; Overmoyer, B; Mittendorf, EA; Bueno-Muiño, C; Martín, M; Prat, A; Tolaney, SM.

HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers5

Esmo Open. 2025; 10(2): Nº de citas: 5 [doi:10.1016/j.esmoop.2024.104100]

Martin-Liberal, J; Márquez-Rodas, I; Cerezuela-Fuentes, P; Soria, A; Garicano, F; Medina, J; Galindo, RG; Oramas, J; Manzano, JL; Delgado, M; Valdivia, J; Sanchez, P.

Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases

CANCER TREATMENT REVIEWS. 2025; 133: Nº de citas: 3 [doi:10.1016/j.ctrv.2025.102886]

Martín, M; Stecklein, SR; Gluz, O; Villacampa, G; Monte-Millán, M; Nitz, U; Cobo, S; Christgen, M; Brasó-Maristany, F; Alvarez, EL; Echavarría, I; Conte, B; Kuemmel, S; Bueno-Muiño, C; Jerez, Y; Kates, R; Cebollero, M; Kolberg-Liedtke, C; Bueno, O; García-Saenz, JA; Moreno, F; Grischke, EM; Forstbauer, H; Braun, M; Warm, M; Hackmann, J; Uleer, C; Aktas, B; Schumacher, C; Wuerstleins, R; Graeser, M; zu Eulenburg, C; Kreipe, HH; Gómez, H; Massarrah, T; Herrero, B; Paré, L; Bohn, U; López-Tarruella, S; Vivanco, A; Sanfeliu, E; Parker, JS; Perou, CM; Villagrasa, P; Prat, A; Sharma, P; Harbeck, N.

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

ANNALS OF ONCOLOGY. 2025; 36(2): 158-171 Nº de citas: 15 [doi:10.1016/j.annonc.2024.10.012]

Demichele, A; Dueck, AC; Hlauschek, D; Martin, M; Burstein, H; Pfeiler, G; Zdenkowski, N; Wolff, A; Bellet-Ezquerra, M; Winer, E; Balic, M; Miller, K; Colleoni, M; Lake, D; Rubovsky, G; Cameron, D; Balko, J; Singer, CF; Nowecki, Z; Iwata, H; Wolmark, N; Parraga, KA; Rugo, H; Steger, GG; Traina, T; Werutsky, G; Czajkowska, D; Metzger, O; El-Abed, S; Theall, KP; Lu, RD; O'Brien, P; Fesl, C; Mayer, E; Gnant, M.

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])

BREAST CANCER RESEARCH. 2025; 27(1): Nº de citas: 2 [doi:10.1186/s13058-024-01941-3]

Amaral, T; Nanz, L; Higuita, LMS; Ascierto, P; Berking, C; Couselo, EM; Donia, M; Dummer, R; Gutzmer, R; Haushild, A; Jalving, M; Lee, RBC; Lorigan, P; Marquez-Rodas, I; Michelin, O; Nathan, P; Robert, C; Schadendorf, D; Sobczuk, P; Flatz, L; Leiter, U; Garbe, C.

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

EUROPEAN JOURNAL OF CANCER. 2025; 215: Nº de citas: 1 [doi:10.1016/j.ejca.2024.115160]

Lenz, HJ; Liu, TS; Chen, EY; Horváth, Z; Bondarenko, I; Danielewicz, I; Ghidini, M; García-Alfonso, P; Jones, R; Aapro, M; Zhang, YQ; Wang, JF; Wang, WY; Adeleye, J; Beelen, A; Hubbard, J.

Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial

Jnci Cancer Spectrum. 2025; 9(1): Nº de citas: 4 [doi:10.1093/jncics/pkae116]

Wolchok, JD; Chiarion-Sileni, V; Rutkowski, P; Cowey, CL; Schadendorf, D; Wagstaff, J; Queirolo, P; Dummer, R; Butler, MO; Hill, AG; Postow, MA; Gaudy-Marqueste, C; Medina, T; Lao, CD; Walker, J; Márquez-Rodas, I; Haanen, JBAG; Guidoboni, M; Maio, M; Schöffski, P; Carlino, MS; Sandhu, S; Lebbé, C; Ascierto, PA; Long, GV; Ritchings, C; Nassar, A; Askelson, M; Benito, MP; Wang, WJ; Hodi, FS; Larkin, J.

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

NEW ENGLAND JOURNAL OF MEDICINE. 2025; 392(1): Nº de citas: 312 [doi:10.1056/NEJMoa2407417]

Robert C; Long GV; Larkin J; Wolchok JD; Hassel JC; Schadendorf D; Hodi FS; Lebbé C; Grob JJ; Hyngstrom JR; Wagstaff J; Chesney J; Butler MO; Bechter O; Márquez-Rodas I; Pavlick AC; Durani P; Pe Benito M; Wang P; Postow MA; Ascierto PA.

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.

EUROPEAN JOURNAL OF CANCER. 2025; 214: 115119-115119 Nº de citas: 11 [doi:10.1016/j.ejca.2024.115119]

Calles, A; Alonso, M; Martín-Martorell, P; Gómez, A; de Castro, J; Martínez-Aguillo, M; Estival, A; Mosquera, J; Martínez-Banaclocha, N; Majem, M; Reyes, R; Azkona, E; Ortega, AL; Aguin, S; Santos, A; Aguilar, A; Cucurull, M; Blasco, A; Calvo, V; Isla, D; Nadal, E; Aguado, C; Sais, E; Juan-Vidal, O; Diz-Taín, M; Taus, A; Villanueva, N; Bayona, C; Amenedo, M; Mielgo, X; Arriola, E; Baena, J.

Efficacy and safety of lorlatinib in patients with ALK-and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain

Cancer Treatment and Research Communications. 2025; 43: Nº de citas: 2 [doi:10.1016/j.ctarc.2025.100905]

Isla, D; Alvarez, R; Arnal, M; Arriola, E; Azkarate, A; Azkona, E; García-Campelo, R; Garrido, P; Nadal, E; Ortega, AL; Carcedo, D; Crespo, M; Lavara, J; Córcoles, F; Bernabé, R.

Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis

Journal of Medical Economics. 2024; 27(1): 1379-1387 Nº de citas: 4 [doi:10.1080/13696998.2024.2413289]

Lin, CC; Garralda, E; Schoeffski, P; Hong, DS; Siu, LL; Martin, M; Maur, M; Hui, RA; Soo, RA; Chiu, J; Zhang, T; Ma, BGT; Kyi, C; Tan, DS; Cassier, PA; Sarantopoulos, J; Weickhardt, A; Carvajal, RD; Spratlin, J; Esaki, T; Rolland, F; Akerley, W; Deschler-Baier, B; Rispoli, L; Samant, TS; Chowdhury, NR; Gusenleitner, D; Kwak, EL; Askoxylakis, V; De Braud, F.

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

OncoImmunology. 2024; 13(1): 2290787-2290787 Nº de citas: 23 [doi:10.1080/2162402X.2023.2290787]

Piedra, A; Martínez-Recio, S; Hernández, A; Morán, T; Arriola, E; Recuero-Borau, J; Cobo, M; Cordeiro, P; Mosquera, J; Fernández, M; García-Campelo, R; Calles, A; Alvarez, R; Zapata-García, M; Isla, D; Callejo, A; Iranzo, P; Serra-López, J; Barba, A; Sullivan, I; Felip, E; Majem, M.

First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study

Frontiers in Oncology. 2024; 14: Nº de citas: 2 [doi:10.3389/fonc.2024.1510278]

Hamilton, E; Galsky, MD; Ochsenreither, S; Del Conte, G; Martín, M; De Miguel, MJ; Yu, EY; Williams, A; Gion, M; Tan, AR; Agrawal, L; Rutten, A; Machiels, JP; Cresta, S; Debruyne, PR; Hennequin, A; Moreno, V; Minchom, A; Valdes-Albini, F; Petrylak, D; Li, L; Tsuchihashi, Z; Suto, F; Cheng, FC; Kandil, M; Barrios, D; Hurvitz, S.

Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study

CLINICAL CANCER RESEARCH. 2024; 30(24): 5548-5558 Nº de citas: 31 [doi:10.1158/1078-0432.CCR-24-1513]

Jhaveri, KL; Lim, E; Jeselsohn, R; Ma, CX; Hamilton, EP; Osborne, C; Bhave, M; Kaufman, PA; Beck, JT; Sanchez, LM; Parajuli, R; Wang, HC; Tao, JJ; Im, SA; Harnden, K; Yonemori, K; Dhakal, A; Neven, P; Aftimos, P; Pierga, JY; Lu, YS; Larson, T; Jerez, Y; Sideras, K; Sohn, J; Kim, SB; Saura, C; Bardia, A; Sammons, SL; Bacchion, F; Li, YJ; Yuen, E; Estrem, ST; Rodrik-Outmezguine, V; Nguyen, B; Ismail-Khan, R; Smyth, L; Beeram, M.

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(35): Nº de citas: 27 [doi:10.1200/JCO.23.02733]

Neven, P; Stahl, N; Vidal, M; Martin, M; Kaufman, PA; Harbeck, N; Hunt, KK; Carter, S; Bidard, FC; Fasching, PA; Aftimos, P; Wheatley, D; Hamilton, E; Aft, R; Kulkarni, S; Schmid, P; Bhave, M; Ismail-Khan, R; Karacsonyi, C; Estrem, ST; Nguyen, B; Ozbek, U; Yuen, E; Rodrik-Outmezguine, V; Ciruelos, E.

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study

CLINICAL CANCER RESEARCH. 2024; 30(23): 5304-5313 Nº de citas: 6 [doi:10.1158/1078-0432.CCR-24-2113]

de la Haba-Rodríguez, JR; Mínguez, P; Rojo, F; Martín, M; Alba, E; Servitja, S; Prat, A; Pérez-Fidalgo, JA; Gavilá, J; Morales, C; Rodriguez-Lescure, A; Herrero, C; Peña-Enriquez, R; Herranz, J; Hernando, C; Hernández-Blanquisett, A; Guil-Luna, S; Martinez, MT; Blanch, S; Caballero, R; Martín, N; Pollán, M; Guerrero-Zotano, A; Bermejo, B.

Gestational breast cancer: distinctive molecular and clinico-epidemiological features

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA. 2024; 29(1): Nº de citas: 4 [doi:10.1007/s10911-024-09571-3]